FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 401 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma October 6, 2022 ScottishPower supports vital research into air pollution and cancer November 24, 2022 Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated,... January 30, 2026 First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 Load more HOT NEWS 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout To Combat Cancer Treatment Resistance, Researchers Try Leveraging Evolution Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients... FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection...
